Design Therapeutics (DSGN) Equity Ratio (2020 - 2026)

Design Therapeutics has disclosed Equity Ratio across 7 years of filings, most recently posting 0.95 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.95, down 1.41% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.95 (down 1.41% YoY), and the FY2025 annual result was 0.94, down 2.18% from the prior year.
• Equity Ratio came in at 0.95 for Q1 2026 at Design Therapeutics, up from 0.94 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.98 in Q1 2022 to a low of 0.94 in Q4 2025.
• The 5-year median for Equity Ratio is 0.96 (2025), against an average of 0.96.
• Across the five-year window, Equity Ratio climbed 1.75% in 2024 and slipped 2.26% in 2025, its largest moves.
• Design Therapeutics' Equity Ratio stood at 0.96 in 2022, then declined by 0.08% to 0.96 in 2023, then rose by 0.17% to 0.96 in 2024, then slipped by 2.18% to 0.94 in 2025, then gained by 0.72% to 0.95 in 2026.
• The last three Equity Ratio figures came in at 0.95 (Q1 2026), 0.94 (Q4 2025), and 0.94 (Q3 2025), per Business Quant data.